Original articleArylazolylthioacetanilide. Part 8☆: Design, synthesis and biological evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides As Potent HIV-1 inhibitors☆

Add time:09/05/2019    Source:sciencedirect.com

The development of novel HIV-1 NNRTIs offers the possibility of generating novel structures with increased potency. Based on the bioisosteric principle, a novel series of 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamide derivatives were designed, synthesized using a simple and efficient synthetic route, structurally confirmed by spectral analysis, evaluated for their anti-HIV activity in MT-4 cells and their inhibitory effect on HIV-1 RT. The results showed that some of the new compounds displayed low micromolar potency for inhibiting HIV-1 replication and promising activities against several selected resistant strains that confer resistance to current NNRTIs. However, all newly synthesized derivatives were not active against HIV-2 replication.

We also recommend Trading Suppliers and Manufacturers of 4-BROMO-3-(2,4-DICHLOROPHENYL)-1-METHYL-1H-PYRAZOLE (cas 133112-51-3). Pls Click Website Link as below: cas 133112-51-3 suppliers

Prev:Novel ketoconazole analogues based on the replacement of 2,4-dichlorophenyl group with 1,4-benzothiazine moiety: Design, synthesis, and microbiological evaluation
Next:Short communicationAliphatic ethers of 1-(2,4-dichlorophenyl)-2-(1-H-imidazolyl)ethanol: influence of ramification and/or unsaturation on lipophilicity and antifungal activity)